Journal of Clinical Oncology - ASCO Publications
WEBSep 17, 2024 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Management of Immune-Related Adverse Events in Patients …
WEBImmunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize and attack cancer ...
ASCO Publications
WEBFounded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 · Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. 1 Almost 150,000 new cases and more than 50,000 deaths from CRC are reported each year in the United States. 2 In recent decades, the overall incidence of CRC has decreased among older adults because of screening and lifestyle factors; however, at the same time, incidence is increasing among younger adults. 3 ...
Survival in Patients With Brain Metastases: Summary Report on the ...
WEBSep 15, 2020 · Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups.Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3 ...
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
WEBIn the United States, it is estimated that between 8% and 10% of patients with cancer will develop brain metastases representing approximately 200,000 new patients with brain metastases every year. 1 The point prevalence of brain metastases on initial diagnosis varies widely between different cancer histologies. For example, the incidence proportion of patients with metastatic cancer who have ...
Does size matter? Lesion size as an indicator of number of cores …
WEBFeb 19, 2020 · Background: MRI/US fusion guided prostate biopsy (FBx) has been shown to detect clinically significant prostate cancer (csCaP) at higher rates and with fewer cores than standard prostate biopsy. Size plays an important role in assigning a suspicion level (PI-RADS) to lesions identified on MRI. However, tumor characteristics may pose challenges to accurately characterizing the lesion despite ...
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
WEBInitial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update April 3, 2023. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline June 21, 2022. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline December 12, 2019. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO ...
Evidence-Based Management of Oral Mucositis | JCO Oncology …
WEBFeb 3, 2020 · As well described in the clinical review by Brown and Gupta 1 in this issue of JCO Oncology Practice, oral mucositis is a common toxicity of cancer therapy.The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy.
Antiemetics: ASCO Guideline Update | Journal of Clinical Oncology
WEBJul 13, 2020 · The systematic reviews included 3 publications from the updated search and 10 publications on CPIs. Two phase III trials in adult patients with non–small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the prophylactic antiemetic regimen.